COVID and lung cancer: How experts in cancer and virology joined forces in a challenging time

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage is available here.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System;
Professor of medicine and pathology, Icahn School of Medicine;
Joe Lowe and Louis Price Professor of Medicine,
Associate director, Tisch Cancer Institute

YOU MAY BE INTERESTED IN

President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...

Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System;
Professor of medicine and pathology, Icahn School of Medicine;
Joe Lowe and Louis Price Professor of Medicine,
Associate director, Tisch Cancer Institute